## 1 Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis

# 2 and hospitalization in older adults

- 3
- 4 Katia J. Bruxvoort, PhD,<sup>1,2\*†</sup> Bradley Ackerson, MD,<sup>1†</sup> Lina S. Sy, MPH,<sup>1</sup> Amit Bhavsar,
- 5 MBBS, MHA,<sup>3</sup> Hung Fu Tseng, PhD,<sup>1,4</sup> Ana Florea, PhD,<sup>1</sup> Yi Luo, PhD,<sup>1</sup> Yun Tian, MS,<sup>1</sup>
- <sup>6</sup> Zendi Solano, BS,<sup>1</sup> Robyn Widenmaier, MBiotech,<sup>5</sup> Meng Shi, MS,<sup>5</sup> Robbert Van Der
- 7 Most, PhD,<sup>6</sup> Johannes Eberhard Schmidt, MD, MPH,<sup>7</sup> Jasur Danier, MD,<sup>5</sup> Thomas
- 8 Breuer, MD, MSc,<sup>3</sup> Lei Qian, PhD<sup>1</sup>
- 9
- <sup>1</sup>Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S
- 11 Los Robles, Pasadena, CA 91101, USA
- <sup>12</sup> <sup>2</sup>Department of Epidemiology, University of Alabama at Birmingham, 1665 University
- 13 Blvd, Birmingham, AL 35233, USA
- <sup>14</sup> <sup>3</sup>GSK, 20 Avenue Fleming, 1300 Wavre, Belgium
- <sup>15</sup> <sup>4</sup>Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave.,
- 16 Pasadena, CA 91101, USA
- <sup>17</sup> <sup>5</sup>GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA
- <sup>18</sup> <sup>6</sup>GSK, 89 Rue de l'Institut, 1330 Rixensart, Belgium
- <sup>19</sup> <sup>7</sup>GSK, 1 Via Fiorentina, 53100 Siena, Italy
- 20
- 21 \*Address for correspondence: <u>kbruxvoort@uab.edu</u>
- <sup>1</sup>KJB and BA contributed equally to this work.
- 23

## 24 Running Title: RZV and reduced COVID-19risk

25

Dr. Ackerson, Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Solano, Ms. Sy, Ms. 26 27 Tian, and Dr. Tseng received research funding from the GSK group of companies for work related to this paper. Dr. Ackerson, Dr. Bruxvoort, Dr. Qian, Ms. Solano, and Ms. 28 Sy received research funding from Dynavax for work unrelated to this paper. Dr. 29 Ackerson, Dr. Bruxvoort, Dr. Luo, Ms. Sy, and Dr. Tseng received research funding 30 from Segirus for work unrelated to this paper. Dr. Bruxvoort, Dr. Florea, and Ms. Solano 31 received research funding from Gilead for work unrelated to this paper. Dr. Ackerson, 32 Dr. Bruxvoort, Dr. Florea, Dr. Luo, Dr. Qian, Ms. Sy, Ms. Tian, and Dr. Tseng received 33 research funding from Moderna for work unrelated to this paper. Dr. Ackerson, Dr. 34 Bruxvoort, and Dr. Florea received research funding from Pfizer for work unrelated to 35 this paper. KPSC received consultation fees for Dr. Tseng's consultation work with 36 Johnson and Johnson. Dr. Bhavsar, Ms. Widenmaier, Mr. Shi, Dr. Van Der Most, Dr. 37 Schmidt, Dr. Danier, and Dr. Breuer were employees of the GSK group of companies at 38 the time of the study conduct. Ms. Widenmaier, Dr. Van Der Most, Dr. Schmidt, Dr. 39 Danier, and Dr. Breuer hold shares in the GSK group of companies. All authors do not 40 have any non-financial relationships and activities to declare. 41

This work was supported by GlaxoSmithKline Biologicals SA. Costs associated with
manuscript editorial and coordination support were covered by GlaxoSmithKline
Biologicals SA.

45

- 47 Corresponding author:
- 48 Katia Bruxvoort, PhD MPH
- 49 Department of Epidemiology, University of Alabama at Birmingham, 1665 University
- 50 Blvd, Birmingham, AL 35233, USA
- 51 Phone: 205-975-8625
- 52 Email: kbruxvoort@uab.edu

## 53 Abstract

- 54 **Background:** Vaccines may elicit long-term boosting of innate immune responses that can
- 55 help protect against COVID-19. We evaluated the association between recombinant
- <sup>56</sup> adjuvanted zoster vaccine (RZV) and COVID-19 outcomes at Kaiser Permanente Southern

57 California.

- 58 **Methods:** In a cohort design, adults aged  $\geq$ 50 years who received  $\geq$ 1 RZV dose prior to
- <sup>59</sup> 3/1/2020 were matched 1:2 to unvaccinated individuals and followed until 12/31/2020.
- 60 Adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) for COVID-19
- outcomes were estimated using Cox proportional hazards regression. In a test-negative
- design, cases had a positive SARS-CoV-2 test and controls had only negative tests,
- from 3/1/2020-12/31/2020. Adjusted odds ratios (aOR) and 95% CIs for prior receipt of
- 64 RZV were estimated using logistic regression.
- 65 **Results:** In the cohort design, 149,244 RZV recipients were matched to 298,488
- <sup>66</sup> unvaccinated individuals. The aHRs (95% CI) for COVID-19 diagnosis and
- hospitalization were 0.84 (0.81-0.87) and 0.68 (0.64-0.74), respectively. In the test-
- negative design, 8.4% of 75,726 test-positive cases and 13.1% of 340,898 test-negative
- controls had received ≥1 RZV dose. The aOR (95% CI) was 0.84 (0.81-0.86).
- 70 Conclusion: RZV vaccination was associated with a 16% lower risk of COVID-19
- diagnosis and 32% lower risk of hospitalization, suggesting RZV elicits heterologous

72 protection, possibly through trained immunity.

73

74 Keywords: COVID-19, zoster vaccine, trained immunity, non-specific effects

# 75 Background

76	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes
77	coronavirus disease 2019 (COVID-19) has triggered a global pandemic with over 224
78	million infections and more than 4.6 million deaths.[1] Despite the extraordinary pace of
79	COVID-19 vaccine development, nearly 12 months were required to develop, evaluate,
80	and initiate large-scale production and administration of highly effective vaccines.[2] As
81	of September 2021, COVID-19 vaccines have been available for over 9 months, but
82	nearly 58% of the global population remains unvaccinated, despite ongoing efforts to
83	increase global vaccine production and distribution.[3]
84	Traditionally, immune memory consisting of pathogen-specific cellular and humoral
85	responses was thought to be the hallmark of the adaptive response. However, a
86	growing body of evidence suggests that the innate immune system can also develop
87	and maintain immune memory (i.e. trained immunity), which may be helpful in reducing
88	the impact of a broad array of infectious diseases.[4-6] Several studies with vaccines,
89	including the tuberculosis vaccine Bacillus Calmette-Guérin (BCG), and measles, oral
90	polio, and influenza vaccines, including vaccine adjuvants, demonstrate the ability of the
91	innate immune system to form memory and to provide non-specific protection against
92	heterologous infections.[5-9]
93	Recombinant adjuvanted zoster vaccine (RZV) is the first approved and widely used
94	vaccine with the novel AS01 adjuvant, which elicits an innate immune response and
95	robust cellular and humoral responses.[10, 11] We hypothesized that RZV could induce
96	trained immunity that might reduce SARS-CoV-2 infections in older adults, who are at

97 high risk of severe disease and poor outcomes following SARS-CoV-2 infection.[12]

98 Therefore, we evaluated the association of receipt of RZV with COVID-19 diagnosis and

99 COVID-19-associated hospitalizations in a large cohort of adults aged ≥50 years.

- 100 Methods
- 101 Study setting

102 We employed both matched cohort and test-negative designs in an observational study

103 conducted at Kaiser Permanente Southern California (KPSC), an integrated health care

104 system with 15 hospitals and 235 associated medical office buildings. The KPSC

population of over 4.6 million members is stable and mirrors the sociodemographic,

106 racial, and ethnic diversity of Southern California.[13] KPSC members are incentivized

107 to seek care within the KPSC system, and recommended vaccinations are proactively

108 offered free of charge at any visit or at walk-in nurse clinic visits. Comprehensive

109 electronic health records (EHR) capture all details of patient care, including diagnoses,

110 vaccinations, procedures, laboratory tests, and pharmacy records. Care received

111 outside of KPSC is captured through claims.

112 Molecular diagnostic testing for SARS-CoV-2 evolved during the study period (3/1/2020-

113 12/31/2020). In the early months of the pandemic, testing was prioritized for individuals

114 with symptoms and prior to hospital admissions or certain outpatient procedures. RT-

115 PCR was primarily conducted on nasopharyngeal/oropharyngeal swabs using the

116 Roche cobas<sup>®</sup> SARS-CoV-2 assay on the Roche cobas<sup>®</sup> 6800 and 8800 analyzers

117 (Roche Molecular Systems, New Jersey, USA) or the Aptima<sup>®</sup> SARS-CoV-2 assay on

<sup>118</sup> Hologic Panther<sup>®</sup> analyzers (Hologic Inc, San Diego, California, USA). However, testing

119 guidelines were gradually expanded, such that by September 2020 testing was widely

available for symptomatic and asymptomatic individuals for any reason. By November

121	2020, implementation of saliva testing and a new COVID-19 laboratory using the
122	TaqPath™ COVID-19 High-Throughput Combo Kit on the Thermo Fisher Scientific
123	Amplitude Solution (Thermo Fisher Scientific, California, USA) increased testing
124	capacity at KPSC to approximately 52,000 tests per day.
125	Cohort design
126	The cohort design included individuals aged ≥50 years as of 3/1/2020 who had at least
127	1-year prior KPSC membership (allowing for a 31-day gap). Separate analyses were
128	conducted defining the exposure as either receipt of at least 1 dose of RZV prior to
129	3/1/2020, receipt of 2 doses of RZV $\geq$ 4 weeks apart prior to 3/1/2020, or receipt of 1
130	dose of RZV only prior to 3/1/2020. Outcomes were COVID-19 diagnosis, defined as a
131	positive SARS-CoV-2 molecular test or COVID-19 diagnosis code (Supplementary
132	Table 1), and COVID-19 hospitalization, defined as a hospitalization with a SARS-CoV-
133	2 positive test or a COVID-19 diagnosis, or a hospitalization occurring within 7 days
134	after a SARS-CoV-2 positive test. We excluded individuals with COVID-19 outcomes
135	occurring ≤14 days after receipt of RZV.
136	Recipients of at least 1 dose of RZV as of 3/1/2020 were matched 1:2 with RZV
137	unvaccinated individuals by age (50-59 years, 60-69 years, 70-79 years, and $\ge$ 80
138	years), sex, race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, non-
139	Hispanic Asian, and other/unknown), and zip code. Individuals were followed through
140	EHR from 3/1/2020 until occurrence of COVID-19 outcomes, termination of
141	membership, death, receipt of a first dose of RZV for unvaccinated individuals, or end of
142	the study period (12/31/2020), whichever came first.

We identified clinical characteristics in the year prior to 3/1/2020 including: most recent 143 body mass index (BMI), most recent smoking status, health care utilization (number of 144 outpatient visits, number of emergency department [ED] visits, number of 145 hospitalizations), frailty using the algorithm described by Kim et al.,[14] comorbidities 146 (cardiovascular disease, diabetes, hypertension, pulmonary disease, renal disease, 147 cancer, autoimmune disease using International Classification of Diseases Tenth 148 *Revision (ICD-10)* codes, [15] and HIV using the KPSC HIV registry), other vaccinations 149 150 (influenza, pneumococcal, and tetanus, diphtheria, and acellular pertussis [Tdap]), and 151 medical center area. We used similar methods for the analysis comparing recipients of at least 1 dose of 152 RZV and their unvaccinated matches, the analysis comparing recipients of 2 doses of 153 154 RZV and their unvaccinated matches, and the analysis comparing recipients of 1 dose of RZV only and their unvaccinated matches. We first described characteristics of RZV 155 vaccinated and RZV unvaccinated individuals, reporting absolute standardized 156 157 differences (ASD) to assess balance between covariates; characteristics that were substantially different between RZV vaccinated and unvaccinated groups (ASD >0.1) 158 159 were considered potential confounders for inclusion in multivariable analyses. We calculated incidence rates for COVID-19 outcomes by dividing the number of COVID-19 160 outcomes by the total number of person-years, and we used the Kaplan-Meier method 161 162 to estimate cumulative incidence. Finally, we used Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for COVID-19 163 outcomes comparing RZV vaccinated and unvaccinated individuals, adjusting for 164 165 potential confounders. To further control for differences in health care seeking behavior

by vaccination status and potential effect modification due to receipt of other vaccines,
sensitivity analyses were conducted to compare the risk of COVID-19 outcomes among
RZV vaccinated and unvaccinated individuals, in a subset of individuals who had
received influenza vaccine but no other vaccines in the year prior to 3/1/2020. Analyses
comparing recipients of at least 1 dose of RZV and their unvaccinated matches were
performed among this subset of individuals.

## 172 Test-negative design

173 The test-negative design included all individuals tested for SARS-CoV-2 from 3/1/2020

to 12/31/2020, who had at least 1-year prior membership (allowing for a 31-day gap)

and were aged ≥50 years as of the SARS-CoV-2 test date. Test-positive cases

176 comprised individuals with a positive SARS-CoV-2 test, and test-negative controls

177 comprised those with only negative SARS-CoV-2 tests during the same period. For

individuals with multiple SARS-CoV-2 tests, the test-positive case was defined as the

179 first positive test for individuals with any positive tests, and the test-negative control was

defined as the first negative test for individuals with only negative tests. Separate

analyses were conducted defining the exposure as either receipt of at least 1 dose of

182 RZV  $\geq$ 14 days prior to the SARS-CoV-2 test or receipt of 2 doses of RZV  $\geq$ 4 weeks

apart ≥14 days prior to the SARS-CoV-2 test. Individuals who received RZV <14 days

prior to the SARS-CoV-2 test were excluded from the study.

185 We described characteristics of test-positive cases and test-negative controls in the

186 year prior to their SARS-CoV-2 test date, using similar methods as for the cohort

design. We used logistic regression to estimate odds ratios (OR) and 95% CI comparing

odds of RZV vaccination among test-positive cases and test-negative controls, adjusting

189 for age, sex, race/ethnicity, calendar time, and other confounders based on ASD >0.1.

- 190 We also conducted analyses stratifying the RZV exposure by time from most recent
- 191 RZV dose to SARS-CoV-2 test (15 days to <1 month, 1 to <6 months, 6 months to <1
- 192 year, and  $\geq 1$  year).
- 193 The KPSC Institutional Review Board reviewed and approved the study with a waiver
- 194 for the requirement of informed consent.
- 195 **Results**
- 196 Cohort design receipt of at least 1 dose of RZV

197 The cohort design with at least 1 dose of RZV as the exposure included 149,244 RZV

vaccinated individuals and 298,488 matched RZV unvaccinated individuals (**Table 1**).

199 Overall, 16.2% were aged 50-59 years and 12.8% were  $\geq$ 80 years, 57.8% were female,

- and 54.1% were non-Hispanic White. Recipients of at least 1 dose of RZV had less
- 201 missing data on BMI (2.6% vs 13.2% of matched RZV unvaccinated individuals, ASD

0.41) and on smoking (2.7% vs 12.7%, ASD 0.39), and had more outpatient visits in the

203 year prior to 3/1/2020 (39.1% vs 28.8% with ≥11 visits, ASD 0.49). They more

commonly had hypertension (49.0% vs 43.9%, ASD 0.10) and had received other

vaccinations (93.6% vs 73.3%, ASD 0.57) in the year prior. Other characteristics,

including the number of ED visits and hospitalizations, frailty, other comorbidities in the

207 year prior, and medical center area, were well-balanced between recipients of at least 1

dose of RZV and their RZV unvaccinated matches.

Among recipients of at least 1 dose of RZV, there were 5,951 COVID-19 diagnoses and

1,066 COVID-19 hospitalizations, with incidence rates per 1,000 person-years (95% CI)

of 48.82 (47.60-50.08) and 8.69 (8.18-9.23), respectively (**Table 2**). Among RZV

212	unvaccinated individuals matched to recipients of at least 1 dose of RZV, there were
213	13,028 COVID-19 diagnoses and 2,765 COVID-19 hospitalizations, with incidence rates
214	per 1,000 person-years of 55.01 (54.07-55.96) and 11.59 (11.17-12.03), respectively. In
215	Kaplan-Meier analyses, the cumulative incidences of COVID-19 diagnosis and COVID-
216	19 hospitalization were lower among recipients of at least 1 dose of RZV compared to
217	their RZV unvaccinated matches (Figure 1-2). In fully adjusted analyses, recipients of at
218	least 1 dose of RZV had a 16% lower rate of COVID-19 diagnosis (HR 0.84 [95% CI:
219	0.81-0.87]) and a 32% lower rate of COVID-19 hospitalization (HR 0.68 [95% CI: 0.64-
220	0.74]) compared to RZV unvaccinated individuals (Table 2).
221	In sensitivity analyses among the subset of individuals who had received influenza
222	vaccine but no other vaccines in the year prior to 3/1/2020, we observed similar
223	reductions in COVID-19 diagnosis and hospitalization among recipients of at least 1
224	dose of RZV compared to RZV unvaccinated individuals (Supplementary Table 2). In
225	fully adjusted analyses of this subset, recipients of at least 1 dose of RZV had a 17%
226	lower rate of COVID-19 diagnosis (HR 0.83 [95% CI: 0.78-0.89]) and a 32% lower rate
227	of COVID-19 hospitalization (HR 0.68 [95% CI: 0.59-0.78]).
228	Cohort design – receipt of 2 doses of RZV
229	The cohort design with 2 doses of RZV as the exposure included 94,895 RZV
230	vaccinated individuals and 189,790 matched RZV unvaccinated individuals
231	(Supplementary Table 3). Differences in characteristics among recipients of 2 doses of
232	RZV and their RZV unvaccinated matches were similar to the distributions observed for
233	recipients of at least 1 dose of RZV and their RZV unvaccinated matches.

234	Among recipients of 2 doses of RZV, there were 3,403 COVID-19 diagnoses and 612
235	COVID-19 hospitalizations, with incidence rates per 1,000 person-years (95% CI) of
236	43.79 (42.34-45.28) and 7.83 (7.23-8.48), respectively (Table 3). Among unvaccinated
237	individuals matched to recipients of 2 doses of RZV, there were 7,689 COVID-19
238	diagnoses and 1,676 COVID-19 hospitalizations, with incidence rates per 1,000 person-
239	years of 51.03 (49.90-52.19) and 11.05 (10.53-11.59), respectively. In Kaplan-Meier
240	analyses, the cumulative incidences of COVID-19 diagnosis and COVID-19
241	hospitalization were lower among recipients of 2 doses of RZV compared to their RZV
242	unvaccinated matches (Supplementary Figures 1-2). In fully adjusted analyses, those
243	who received 2 doses of RZV had a 19% lower rate of COVID-19 diagnosis (HR 0.81
244	[95% CI: 0.77-0.84]) and a 36% lower rate of COVID-19 hospitalization (HR 0.64 [95%
245	CI: 0.58-0.70]) ( <b>Table 3</b> ).
246	Cohort design – receipt of 1 dose of RZV only
247	The cohort design with 1 dose of RZV only as the exposure included 54,349 RZV
248	vaccinated individuals and 108,698 matched RZV unvaccinated individuals
249	(Supplementary Table 4). Results of this analysis were similar, but less pronounced,
250	than results of the analyses for the other exposures (receipt of at least 1 dose of $RZV$
251	and receipt of 2 doses of RZV). Recipients of 1 dose of RZV only had a 14% lower rate
252	of COVID-19 diagnosis (HR 0.86 [95% CI: 0.82-0.91]) and 24% lower rate of COVID-19
253	hospitalization (HR 0.76 [95% CI: 0.68-0.86]).
254	
	Test-negative design

test-negative controls (Table 4). Cases were younger than controls (49.0% vs 36.1%

257	ages 50-59 years, ASD 0.31) and less often non-Hispanic White (25.2% vs 43.4%, ASD
258	0.50). A higher proportion of cases were obese, and a lower proportion of cases were
259	smokers as compared to controls, but cases also had more missing data for these
260	variables. Cases also had fewer outpatient and ED visits in the year prior to the SARS-
261	CoV-2 test date than controls (16.3% vs 27.8% with ≥11 outpatient visits, ASD 0.36,
262	and 6.5% vs 9.4% with $\ge$ 2 ED visits, ASD 0.14), were less frail (17.8% vs 26.6% in the
263	top quartile of the frailty index, ASD 0.21), less commonly had chronic comorbidities
264	(cardiovascular disease, hypertension, pulmonary disease, renal disease, and cancer),
265	and less commonly had received other vaccinations in the year prior (68.3% vs 76.7%,
266	ASD 0.19). There were also significant differences between cases and controls in test
267	month and medical center area.
268	Of cases and controls, respectively, 8.4% and 13.1% had received at least 1 dose of
269	RZV, 5.4% and 9.2% had received 2 doses of RZV, and 91.6% and 86.9% were RZV $$
270	unvaccinated (Table 5). The adjusted ORs (95% CI) comparing cases and controls
271	were 0.84 (0.81-0.86) for individuals who received at least 1 dose of RZV vs
272	unvaccinated individuals and 0.82 (0.79-0.85) for individuals who received 2 doses of
273	RZV vs unvaccinated individuals. Adjusted ORs did not appear to vary substantially by
274	time since RZV vaccination.
275	Discussion

This large retrospective study spanning the first year of the COVID-19 pandemic
provides evidence from both cohort and test-negative designs that receipt of RZV prior
to the availability of COVID-19 vaccines may have provided benefit in reducing the
burden of COVID-19 in adults aged ≥50 years. In the cohort design analysis, after

280 adjusting for potential confounders including other vaccinations, we found that the risk of COVID-19 diagnosis was reduced by 16% among persons who had received at least 281 1 dose of RZV compared to RZV unvaccinated individuals, an association that was 282 similar and did not vary by time since most recent RZV dose in the test-negative 283 analysis. We also found that the risk of hospitalization with COVID-19 was reduced by 284 32% among recipients of at least 1 dose of RZV compared to RZV unvaccinated 285 individuals. These results were consistent in the test-negative design (16% lower odds 286 of RZV vaccination among SARS-CoV-2 test-positive cases versus test-negative 287 288 controls). A similar reduction in risk of COVID-19 infection and severe disease has been reported 289 following receipt of influenza vaccine in several studies [16-18], although this 290 291 association was not observed in other studies.[19-23] A prior study at KPSC found a reduction in risk of COVID-19 diagnosis and severe disease associated with receipt of 292 13-valent pneumococcal conjugate vaccine (PCV13) but not with receipt of influenza 293 294 vaccine.[24] Interestingly, in a sensitivity analysis among the subset of individuals who received influenza vaccine but no other vaccines, we found that receipt of RZV was still 295 associated with a similar reduction in risk of COVID-19 diagnosis and hospitalization, 296 suggesting that influenza vaccination or healthy vaccinee bias had minimal impact on 297 our findings. 298 299 While the mechanism for the reduced risk of heterologous infections following receipt of some vaccines is not clear, it is plausible that these vaccines induce a trained immune 300 response that results in an improved cytokine response to subsequent exposures; this 301

response may provide an antiviral effect against infection with SARS-CoV-2 or other

303	viruses.[25] Induction of an innate immune response has been suggested as a means
304	to control viral replication early in the course of infection to reduce the risk of severe
305	disease.[4, 9, 25] This may be particularly important for viral infections such as SARS-
306	CoV-2, which appear to attenuate the host innate immune response as a means of
307	increasing viral replication, possibly increasing disease severity and enhancing viral
308	transmission.[26, 27] Notably, induction of innate immunity by highly-effective COVID-
309	19 vaccines has been proposed as a possible mechanism of early protection following
310	vaccination prior to the development of a robust adaptive response.[28] Furthermore,
311	innate immunity has been found to play an important role in the control of infection in
312	coronavirus animal reservoirs and may similarly contribute to reduced severity of
313	COVID-19 disease observed in children compared to adults.[29, 30]
314	Our study found a durable reduction in the risk of COVID-19 infection following receipt
315	of RZV vaccine, consistent with the durable protection against heterologous infections
316	provided by trained immunity.[9] It is possible that the AS01 adjuvant used in RZV,
317	which activates innate immune responses including monocytes and the IFN-response
318	pathways, may be associated with the reduced risk of COVID-19 diagnosis and
319	hospitalization observed in this study.[10, 11, 31] Influenza and other vaccines may also
320	induce similar trained immunity against SARS-CoV-2 infection, although the duration
321	may be variable.[9, 25, 32-34] Additional research is needed to elucidate immunologic
322	mechanisms for our findings and to explore implications such as trained immunity-
323	based vaccines that might mitigate serious infections in future pandemics until specific
324	vaccines become available.[35]

325 Our study had several strengths and limitations. We leveraged comprehensive EHR data on demographic and clinical characteristics, vaccinations, and COVID-19 326 outcomes from a large, diverse cohort of adults aged  $\geq$ 50 years. Although data for BMI 327 328 and smoking status were missing for some individuals, we conducted a sensitivity analysis limited to individuals without missing data and found similar results. As in all 329 observational studies, there may be some residual confounding. RZV recipients may 330 have differed from RZV unvaccinated individuals with respect to health status, health 331 care seeking behavior, and other factors that might, in part, explain the observed 332 333 differences in risk of COVID-19 diagnosis and hospitalization. However, to reduce potential confounding, we used a cohort design, matching RZV recipients with 334 unvaccinated individuals on age, sex, race/ethnicity, and zip code, and adjusting for 335 health care utilization, other vaccinations, and comorbidities. We also used a test-336 negative design, which may be less confounded by health care seeking behavior than 337 the cohort design, [36] but may also be less generalizable given that the study 338 339 population was limited to those who were tested for SARS-CoV-2. We observed similar results using both designs, supporting the validity of the results. In addition, RZV 340 exposure could be misclassified if individuals were vaccinated outside of KPSC; 341 however, such misclassification was likely minimal, because KPSC members received 342 vaccines at KPSC without charge, and providers were required to document previous 343 344 receipt of recommended vaccines at all encounters.

345 **Conclusions:** 

RZV recipients aged ≥50 years had a reduced risk of COVID-19 diagnosis and
 hospitalization compared to RZV unvaccinated individuals, suggesting that RZV may

348	elicit durable innate immune responses that could offer heterologous protection against
349	COVID-19 infection. While this epidemiological study provides further evidence of the
350	concept of trained innate immunity using the adjuvanted RZV vaccine, additional
351	research is needed to identify and understand the underlying non-specific effects of
352	RZV and other vaccines.
353	
354	Acknowledgements
355	The authors thank the members of Kaiser Permanente for helping to improve care
356	through the use of information collected through our electronic health record systems.
357	Editorial and coordination support was provided by Adrian Kremer (Modis c/o GSK).
358	
359	Data Sharing Statement
360	The study details (GSK study number 217021) are available on the GSK Clinical Study
361	Register and can be accessed at www.gskclinicalstudyregister.com.
362	

#### 364 **References**:

- 1. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed September
- 366 14, 2021.
- 367 2. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' interim
- 368 recommendation for use of Pfizer-BioNTech COVID-19 vaccine United States, December 2020. MMWR
- 369 Morb Mortal Wkly Rep **2020**; 69:1922-4.
- 370 3. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Available at:
- 371 <u>https://ourworldindata.org/coronavirus</u>. Accessed September 14, 2021.
- 4. Benn CS, Netea MG, Selin LK, Aaby P. A small jab a big effect: nonspecific immunomodulation by
- 373 vaccines. Trends Immunol **2013**; 34:431-9.
- 5. Goodridge HS, Ahmed SS, Curtis N, et al. Harnessing the beneficial heterologous effects of
- 375 vaccination. Nat Rev Immunol **2016**; 16:392-400.
- 376 6. Wimmers F, Donato M, Kuo A, et al. The single-cell epigenomic and transcriptional landscape of
- immunity to influenza vaccination. Cell **2021**; 184:3915-35 e21.
- 378 7. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent
- 379 nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci
- 380 U S A **2012**; 109:17537-42.
- 381 8. Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral
- infections. Clin Microbiol Infect **2019**; 25:1473-8.
- 383 9. Netea MG, Dominguez-Andres J, Barreiro LB, et al. Defining trained immunity and its role in health
- 384 and disease. Nat Rev Immunol 2020; 20:375-88.
- 10. Coccia M, Collignon C, Herve C, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines
- results in an early IFNgamma response promoting vaccine immunogenicity. NPJ Vaccines **2017**; 2:25.

- 11. Hastie A, Catteau G, Enemuo A, et al. Immunogenicity of the adjuvanted recombinant zoster vaccine:
- 388 persistence and anamnestic response to additional doses administered 10 years after primary
- 389 vaccination. J Infect Dis **2020**: jiaa300.
- 12. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness
- among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ
- 392 **2020**; 369:m1966.
- 393 13. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a
- large, integrated health care system: comparison with US Census Bureau data. Perm J **2012**; 16:37-41.
- 14. Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in medicare
- data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci 2018;
- 397 73:980-7.
- 398 15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM
- and ICD-10 administrative data. Med Care **2005**; 43:1130-9.
- 400 16. Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on
- 401 COVID-19 infection rates and severity. Am J Infect Control **2021**; 49:694-700.
- 402 17. Fink G, Orlova-Fink N, Schindler T, et al. Inactivated trivalent influenza vaccination is associated with
- 403 lower mortality among patients with COVID-19 in Brazil. BMJ Evid Based Med 2020: bmjebm-2020-
- 404 111549.
- 405 18. Huang K, Lin SW, Sheng WH, Wang CC. Influenza vaccination and the risk of COVID-19 infection and
- 406 severe illness in older adults in the United States. Sci Rep **2021**; 11:11025.
- 407 19. Belingheri M, Paladino ME, Latocca R, De Vito G, Riva MA. Association between seasonal flu
- 408 vaccination and COVID-19 among healthcare workers. Occup Med (Lond) **2020**; 70:665-71.
- 409 20. Zein J, Whelan G, Erzurum S. Safety of influenza vaccine during COVID-19. J Clin Transl Sci 2021;
- 410 5:E49.

- 411 21. Kissling E, Hooiveld M, Brytting M, et al. Absence of association between 2019-20 influenza
- 412 vaccination and COVID-19: results of the European I-MOVE-COVID-19 primary care project, March-
- 413 August 2020. Influenza Other Respir Viruses **2021**; 15:429-38.
- 414 22. Martinez-Baz I, Trobajo-Sanmartin C, Arregui I, et al. Influenza vaccination and risk of SARS-CoV-2
- 415 infection in a cohort of health workers. Vaccines (Basel) **2020**; 8:611.
- 416 23. Pedote PD, Termite S, Gigliobianco A, Lopalco PL, Bianchi FP. Influenza vaccination and health
- 417 outcomes in COVID-19 patients: a retrospective cohort study. Vaccines (Basel) 2021; 9:358.
- 418 24. Lewnard JA, Bruxvoort KJ, Fischer H, et al. Prevention of COVID-19 among older adults receiving
- 419 pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-
- 420 CoV-2 in the respiratory tract. J Infect Dis **2021**: jiab128.
- 421 25. Chumakov K, Avidan MS, Benn CS, et al. Old vaccines for new infections: exploiting innate immunity
- to control COVID-19 and prevent future pandemics. Proc Natl Acad Sci U S A **2021**; 118:e2101718118.
- 423 26. Lei X, Dong X, Ma R, et al. Activation and evasion of type l interferon responses by SARS-CoV-2. Nat
- 424 Commun **2020**; 11:3810.
- 425 27. Yuen CK, Lam JY, Wong WM, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent
- 426 interferon antagonists. Emerg Microbes Infect **2020**; 9:1418-28.
- 427 28. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection
- 428 against COVID-19 in humans. Nat Rev Immunol **2021**; 21:475-84.
- 429 29. Silverstein NJ, Wang Y, Manickas-Hill Z, et al. Innate lymphoid cells and disease tolerance in SARS-
- 430 CoV-2 infection [Preprint]. July 4, 2021 [Cited September 14, 2021] Available from:
- 431 <u>https://doiorg/101101/2021011421249839</u>.
- 432 30. Mallapaty S. Kids and COVID: why young immune systems are still on top. Nature **2021**; 597:166-8.
- 433 31. De Mot L, Bechtold V, Bol V, et al. Transcriptional profiles of adjuvanted hepatitis B vaccines display
- variable interindividual homogeneity but a shared core signature. Sci Transl Med **2020**; 12:eaay8618.

- 435 32. Ragni P, Marino M, Formisano D, et al. Association between exposure to influenza vaccination and
- 436 COVID-19 diagnosis and outcomes. Vaccines (Basel) **2020**; 8:675.
- 437 33. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease
- 438 2019 (COVID-19). Proc Natl Acad Sci U S A **2020**; 117:17720-6.
- 439 34. O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat
- 440 Rev Immunol **2020**; 20:335-7.
- 441 35. Sanchez-Ramon S, Conejero L, Netea MG, Sancho D, Palomares O, Subiza JL. Trained immunity-based
- 442 vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front
- 443 Immunol **2018**; 9:2936.
- 444 36. Ozasa K, Fukushima W. Commentary: Test-negative design reduces confounding by healthcare-
- seeking attitude in case-control studies. J Epidemiol **2019**; 29:279-81.
- 446

#### 448

#### Table 1. Baseline characteristics of RZV (at least 1 dose) vaccinated and unvaccinated cohort

	Vaccinated	Unvaccinated	Absolute
	(N=149244)	(N=298488)	Standardized
	n (%)	n (%)	Difference <sup>d</sup>
Age at index date, years			N/A <sup>c</sup>
50-59	24169 (16.2)	48338 (16.2)	
60-69	56047 (37.6)	112094 (37.6)	
70-79	49986 (33.5)	99972 (33.5)	
≥80	19042 (12.8)	38084 (12.8)	
Sex			N/A <sup>c</sup>
Female	86206 (57.8)	172412 (57.8)	
Male	63038 (42.2)	126076 (42.2)	
Race/Ethnicity			N/A <sup>c</sup>
Non-Hispanic White	80743 (54.1)	161486 (54.1)	
Non-Hispanic Black	8411 (5.6)	16822 (5.6)	
Hispanic	30376 (20.4)	60752 (20.4)	
Non-Hispanic Asian	24434 (16.4)	48868 (16.4)	
Other/Unknown	5280 (3.5)	10560 (3.5)	
Body mass index <sup>a</sup>			0.41
<18.5	1925 (1.3)	4418 (1.5)	
18.5-<25	45482 (30.5)	76156 (25.5)	
25-<30	54387 (36.4)	93932 (31.5)	
30-<35	27736 (18.6)	52216 (17.5)	
35-<40	10398 (7.0)	20911 (7.0)	
40-<45	3647 (2.4)	7511 (2.5)	
≥45	1734 (1.2)	3993 (1.3)	
Unknown	3935 (2.6)	39351 (13.2)	
Smoking <sup>a</sup>			0.39
No	111269 (74.6)	194333 (65.1)	
Yes	34016 (22.8)	66278 (22.2)	
Unknown	3959 (2.7)	37877 (12.7)	
Number of outpatient visits <sup>b</sup>			0.49
0	862 (0.6)	26145 (8.8)	

1-4	33628 (22.5)	95907 (32.1)	
5-10	56401 (37.8)	90503 (30.3)	
≥11	58353 (39.1)	85933 (28.8)	
Number of emergency department vi	isits <sup>b</sup>		0.05
0	121729 (81.6)	238943 (80.1)	
1	19135 (12.8)	39466 (13.2)	
≥2	8380 (5.6)	20079 (6.7)	
Number of hospitalizations <sup>b</sup>			0.01
0	130826 (87.7)	261940 (87.8)	
1	11291 (7.6)	22608 (7.6)	
≥2	7127 (4.8)	13940 (4.7)	
Frailty (top quartile) <sup>b</sup>	37951 (25.4)	73969 (24.8)	0.01
Baseline comorbidities <sup>b</sup>			
Cardiovascular disease	45251 (30.3)	81069 (27.2)	0.07
Diabetes	34703 (23.3)	69237 (23.2)	0.00
Hypertension	73201 (49.0)	131033 (43.9)	0.10
Pulmonary disease	23628 (15.8)	41768 (14.0)	0.05
Renal disease	18965 (12.7)	37487 (12.6)	0.00
Cancer	8484 (5.7)	17322 (5.8)	0.01
HIV	1201 (0.8)	818 (0.3)	0.07
Autoimmune disease	7566 (5.1)	13681 (4.6)	0.02
Other vaccinations <sup>b</sup>	139723 (93.6)	218851 (73.3)	0.57
Influenza vaccine	136984 (98.0)	211906 (96.8)	
PCV13/PPSV23	17920 (12.8)	25737 (11.8)	
Tdap	13806 (9.9)	17254 (7.9)	

Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, pneumococcal polysaccharide vaccine; RZV, recombinant zoster vaccine; Tdap, tetanus, diphtheria, acellular pertussis vaccine <sup>a</sup> Most recent in 365 days prior to 3/1/2020

<sup>a</sup> Most recent in 365 days prior to 5/1/2020 <sup>b</sup> In 365 days prior to 3/1/2020 <sup>c</sup> N/A= not applicable, for matching variable <sup>d</sup> Potential confounders were determined by absolute standardized difference >0.1 Medical center area not shown. There were no significant differences in the distribution of the vaccinated and unvaccinated individuals across the 19 medical center areas.

Table 2. Incidence rates and hazard ratios of COVID-19 diagnosis and hospitalization among vaccinated (at least 1 dose of RZV) versus unvaccinated individuals

		Vaccina (N=1492	ted 44)		Unvaccina (N=2984	ated 88)	Hazard Ra	tio (95% CI)
Outcomes	Number of cases	Number of person-years	Incidence per 1000 person-years (95% CI)	Number of cases	Number of person-years	Incidence per 1000 person-years (95% CI)	Unadjusted	Adjusted <sup>a</sup>
COVID-19 diagnosis	5951	121887.27	48.82 (47.60-50.08)	13028	236826.63	55.01 (54.07-55.96)	0.86 (0.84-0.89)	0.84 (0.81-0.87)
COVID-19 hospitalization	1066	122689.85	8.69 (8.18-9.23)	2765	238530.10	11.59 (11.17-12.03)	0.73 (0.68-0.79)	0.68 (0.64-0.74)

Abbreviations: COVID-19, coronavirus disease 2019; RZV, recombinant zoster vaccine

<sup>a</sup> Adjusted for covariates: body mass index, smoking, number of outpatient visits, hypertension, and other vaccinations.

		Vaccinat	ed		Unvaccinated				
		(N=9489	95)		(N=1897	90)	Hazard Rat	tio (95% CI)	
			Incidence per 1000			Incidence per 1000			
Outcomes	Number Number of	Number of	person-vears	Number	Number of	nerson-vears	Upadjustod	Adjusteda	
Outcomes	of cases	person-vears	person-years	of cases	person-vears	person-years	Unaujusteu	Aujusteu	
			(95% CI)		,	(95% CI)			
COVID-19 diagnosis	3403	77714.97	43.79 (42.34-45.28)	7689	150668.58	51.03 (49.90-52.19)	0.83 (0.80-0.87)	0.81 (0.77-0.84)	
COVID-19 hospitalization	612	78164.05	7.83 (7.23-8.48)	1676	151656.50	11.05 (10.53-11.59)	0.69 (0.63-0.76)	0.64 (0.58-0.70)	

Table 3. Incidence rates and hazard ratios of COVID-19 diagnosis and hospitalization among vaccinated (2 doses of RZV) versus unvaccinated individuals

Abbreviations: COVID-19, coronavirus disease 2019; RZV, recombinant zoster vaccine

<sup>a</sup> Adjusted for covariates: body mass index, smoking, number of outpatient visits, and other vaccinations.

	Test Positive	Test Negative	Absolute
	(N=75726)	(N=340898)	Standardized
	n (%)	n (%)	Difference <sup>c</sup>
Age at index date, years			0.31
50-59	37127 (49.0)	122949 (36.1)	
60-69	23618 (31.2)	109724 (32.2)	
70-79	10478 (13.8)	73786 (21.6)	
≥80	4503 (5.9)	34439 (10.1)	
Sex			0.07
Female	39368 (52.0)	188539 (55.3)	
Male	36358 (48.0)	152359 (44.7)	
Race/Ethnicity			0.50
Non-Hispanic White	19061 (25.2)	147937 (43.4)	
Non-Hispanic Black	5371 (7.1)	33653 (9.9)	
Hispanic	42875 (56.6)	112928 (33.1)	
Non-Hispanic Asian	5627 (7.4)	34226 (10.0)	
Other/Unknown	2792 (3.7)	12154 (3.6)	
Body mass index <sup>a</sup>			0.32
<18.5	337 (0.4)	3860 (1.1)	
18.5-<25	8965 (11.8)	70079 (20.6)	
25-<30	20852 (27.5)	105730 (31.0)	
30-<35	17348 (22.9)	69340 (20.3)	
35-<40	8105 (10.7)	31094 (9.1)	
40-<45	3259 (4.3)	11767 (3.5)	
≥45	1806 (2.4)	6676 (2.0)	
Unknown	15054 (19.9)	42352 (12.4)	
Smoking <sup>a</sup>			0.24
No	48717 (64.3)	219476 (64.4)	
Yes	13358 (17.6)	83795 (24.6)	
Unknown	13651 (18.0)	37627 (11.0)	
Number of outpatient visits <sup>b</sup>			0.36
0	9556 (12.6)	23631 (6.9)	
1-4	32985 (43.6)	114891 (33.7)	
5-10	20824 (27.5)	107629 (31.6)	
≥11	12361 (16.3)	94747 (27.8)	

#### Table 4. Characteristics of SARS-CoV-2 test-positive cases and test-negative controls

Number of emergency department

visits <sup>b</sup>			0.14
0	60668 (80.1)	254199 (74.6)	
1	10127 (13.4)	54731 (16.1)	
≥2	4931 (6.5)	31968 (9.4)	
Number of hospitalizations <sup>b</sup>			0.07
0	65804 (86.9)	288216 (84.5)	
1	6048 (8.0)	31358 (9.2)	
≥2	3874 (5.1)	21324 (6.3)	
Frailty (top quartile) <sup>b</sup>	13452 (17.8)	90699 (26.6)	0.21
Baseline comorbidities <sup>b</sup>			
Cardiovascular disease	13226 (17.5)	92145 (27.0)	0.23
Diabetes	21328 (28.2)	88652 (26.0)	0.05
Hypertension	27689 (36.6)	148543 (43.6)	0.14
Pulmonary disease	9559 (12.6)	57428 (16.8)	0.12
Renal disease	6880 (9.1)	44884 (13.2)	0.13
Cancer	3039 (4.0)	24974 (7.3)	0.14
HIV	269 (0.4)	1604 (0.5)	0.02
Autoimmune disease	2703 (3.6)	17717 (5.2)	0.08
Other vaccinations <sup>b</sup>	51718 (68.3)	261421 (76.7)	0.19
Influenza vaccine	50027 (96.7)	254312 (97.3)	
PCV13/PPSV23	4558 (8.8)	24876 (9.5)	
Tdap	5709 (11.0)	27941 (10.7)	
SARS-CoV-2 test month			0.87
March 2020	3977 (1.2)	740 (1.0)	
April 2020	14834 (4.4)	2011 (2.7)	
May 2020	21942 (6.4)	1516 (2.0)	
June 2020	32736 (9.6)	4018 (5.3)	
July 2020	44639 (13.1)	7440 (9.8)	
August 2020	34386 (10.1)	2815 (3.7)	
September 2020	30468 (8.9)	2094 (2.8)	
October 2020	41914 (12.3)	3151 (4.2)	
November 2020	52420 (15.4)	10916 (14.4)	
December 2020	63582 (18.7)	41025 (54.2)	

Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, pneumococcal polysaccharide vaccine; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Tdap, tetanus, diphtheria, acellular pertussis vaccine

<sup>a</sup> Most recent in 365 days prior to test date <sup>b</sup> In 365 days prior to test date

<sup>c</sup> Potential confounders were determined by absolute standardized difference >0.1

Medical center area not shown. There were significant differences in the distribution of the test-positive and test-negative individuals across the 19 medical center areas.

	Test Po	Test Positive Test Negative (N=75726) (N=340898)		egative		
	(N=75			Odds Ratio (95% CI)		
Exposure	n	%	n	%	Unadjusted	Adjusted <sup>a</sup>
RZV (at least 1 dose) vaccinated	6392	8.4	44786	13.1	0.61 (0.59-0.63)	0.84 (0.81-0.86)
15 days to <1 month <sup>b</sup>	302	0.4	1810	0.5	0.71 (0.63-0.81)	0.79 (0.69-0.90)
1 to <6 months	1703	2.3	10643	3.1	0.68 (0.65-0.72)	0.87 (0.82-0.92)
6 months to <1 year	1697	2.2	14606	4.3	0.50 (0.47-0.52)	0.83 (0.78-0.87)
≥1 year	2690	3.6	17727	5.2	0.65 (0.62-0.68)	0.82 (0.79-0.86)
RZV (2 doses) vaccinated	4108	5.4	31359	9.2	0.56 (0.54-0.58)	0.82 (0.79-0.85)
RZV unvaccinated	69334	91.6	296112	86.9	N/A <sup>c</sup>	N/A <sup>c</sup>

Abbreviation: RZV, recombinant zoster vaccine; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

<sup>a</sup> Adjusted for covariates age, sex, race/ethnicity, calendar time, body mass index, smoking, number of outpatient visits, number of emergency department visits, frailty, cardiovascular disease, hypertension, pulmonary disease, renal disease, cancer, other vaccinations, and medical center area.

<sup>b</sup> Time since most recent RZV vaccination

<sup>c</sup> N/A= not applicable



Figure 1: Cumulative incidence estimates of COVID-19 diagnosis by RZV (at least 1 dose) vaccination status

Abbreviations: COVID-19, coronavirus disease 2019; RZV, recombinant zoster vaccine

#### Figure 2: Cumulative incidence estimates of COVID-19 hospitalization by RZV (at least 1 dose) vaccination status



Abbreviations: COVID-19, coronavirus disease 2019; RZV, recombinant zoster vaccine